Annual Total Long Term Liabilities
$4.46 B
+$777.80 M+21.11%
December 31, 2024
Summary
- As of February 20, 2025, REGN annual total long term liabilities is $4.46 billion, with the most recent change of +$777.80 million (+21.11%) on December 31, 2024.
- During the last 3 years, REGN annual total long term liabilities has risen by +$1.73 billion (+63.22%).
- REGN annual total long term liabilities is now at all-time high.
Performance
REGN Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Long Term Liabilities
$4.46 B
+$6.50 M+0.15%
December 31, 2024
Summary
- As of February 20, 2025, REGN quarterly total long term liabilities is $4.46 billion, with the most recent change of +$6.50 million (+0.15%) on December 31, 2024.
- Over the past year, REGN quarterly long term liabilities has increased by +$777.80 million (+21.11%).
- REGN quarterly long term liabilities is now at all-time high.
Performance
REGN Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Long Term Liabilities Formula
Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities
REGN Long Term Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +21.1% | +21.1% |
| 3 y3 years | +63.2% | +21.1% |
| 5 y5 years | +175.6% | +21.1% |
REGN Long Term Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +63.2% | at high | +63.2% |
| 5 y | 5-year | at high | +175.6% | at high | +184.3% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
Regeneron Pharmaceuticals Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $4.46 B(+21.1%) | $4.46 B(+0.1%) |
| Sep 2024 | - | $4.46 B(+1.9%) |
| Jun 2024 | - | $4.37 B(+15.1%) |
| Mar 2024 | - | $3.80 B(+3.1%) |
| Dec 2023 | $3.68 B(+8.1%) | $3.68 B(+0.6%) |
| Sep 2023 | - | $3.66 B(+3.5%) |
| Jun 2023 | - | $3.54 B(+2.0%) |
| Mar 2023 | - | $3.46 B(+1.6%) |
| Dec 2022 | $3.41 B(+24.7%) | $3.41 B(+1.5%) |
| Sep 2022 | - | $3.36 B(-3.6%) |
| Jun 2022 | - | $3.48 B(+1.7%) |
| Mar 2022 | - | $3.43 B(+25.3%) |
| Dec 2021 | $2.73 B(-20.6%) | $2.73 B(+1.3%) |
| Sep 2021 | - | $2.70 B(+2.8%) |
| Jun 2021 | - | $2.63 B(+1.9%) |
| Mar 2021 | - | $2.58 B(-25.1%) |
| Dec 2020 | $3.44 B(+112.5%) | $3.44 B(-5.0%) |
| Sep 2020 | - | $3.62 B(+117.0%) |
| Jun 2020 | - | $1.67 B(+6.3%) |
| Mar 2020 | - | $1.57 B(-3.1%) |
| Dec 2019 | $1.62 B(+5.5%) | $1.62 B(-3.0%) |
| Sep 2019 | - | $1.67 B(-2.1%) |
| Jun 2019 | - | $1.70 B(-10.2%) |
| Mar 2019 | - | $1.90 B(+23.7%) |
| Dec 2018 | $1.53 B(+3.3%) | $1.53 B(+0.9%) |
| Sep 2018 | - | $1.52 B(+6.0%) |
| Jun 2018 | - | $1.43 B(-6.8%) |
| Mar 2018 | - | $1.54 B(+3.7%) |
| Dec 2017 | $1.48 B(+15.7%) | $1.48 B(-1.7%) |
| Sep 2017 | - | $1.51 B(-2.9%) |
| Jun 2017 | - | $1.56 B(-5.3%) |
| Mar 2017 | - | $1.64 B(+28.1%) |
| Dec 2016 | $1.28 B(+12.2%) | $1.28 B(-6.8%) |
| Sep 2016 | - | $1.38 B(+16.9%) |
| Jun 2016 | - | $1.18 B(-3.5%) |
| Mar 2016 | - | $1.22 B(+6.7%) |
| Dec 2015 | $1.14 B(+80.7%) | $1.14 B(-0.7%) |
| Sep 2015 | - | $1.15 B(+96.1%) |
| Jun 2015 | - | $586.97 M(-15.1%) |
| Mar 2015 | - | $691.01 M(+9.2%) |
| Dec 2014 | $632.76 M(-9.6%) | $632.76 M(-18.6%) |
| Sep 2014 | - | $777.43 M(+5.7%) |
| Jun 2014 | - | $735.66 M(-1.1%) |
| Mar 2014 | - | $744.08 M(+6.3%) |
| Dec 2013 | $700.10 M(+4.3%) | $700.10 M(+2.7%) |
| Sep 2013 | - | $681.52 M(+0.1%) |
| Jun 2013 | - | $681.12 M(+1.3%) |
| Mar 2013 | - | $672.41 M(+0.1%) |
| Dec 2012 | $671.55 M(-2.6%) | $671.55 M(-0.7%) |
| Sep 2012 | - | $676.02 M(-0.5%) |
| Jun 2012 | - | $679.62 M(-0.9%) |
| Mar 2012 | - | $685.75 M(-0.6%) |
| Dec 2011 | $689.58 M(+52.4%) | $689.58 M(+63.6%) |
| Sep 2011 | - | $421.54 M(-2.6%) |
| Jun 2011 | - | $432.96 M(-2.5%) |
| Mar 2011 | - | $443.95 M(-1.9%) |
| Dec 2010 | $452.56 M(+80.4%) | $452.56 M(-1.7%) |
| Sep 2010 | - | $460.54 M(+53.6%) |
| Jun 2010 | - | $299.85 M(+1.0%) |
| Mar 2010 | - | $296.79 M(+18.3%) |
| Dec 2009 | $250.87 M(+14.5%) | $250.87 M(+22.0%) |
| Sep 2009 | - | $205.58 M(-2.8%) |
| Jun 2009 | - | $211.41 M(+25.9%) |
| Mar 2009 | - | $167.99 M(-23.3%) |
| Dec 2008 | $219.03 M(+13.9%) | $219.03 M(+28.0%) |
| Sep 2008 | - | $171.19 M(-2.9%) |
| Jun 2008 | - | $176.31 M(-4.3%) |
| Mar 2008 | - | $184.32 M(-4.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2007 | $192.33 M(-40.5%) | $192.33 M(-40.8%) |
| Sep 2007 | - | $325.01 M(+3.6%) |
| Jun 2007 | - | $313.69 M(-2.3%) |
| Mar 2007 | - | $321.14 M(-0.7%) |
| Dec 2006 | $323.45 M(+20.2%) | $323.45 M(+24.4%) |
| Sep 2006 | - | $260.01 M(-1.2%) |
| Jun 2006 | - | $263.06 M(-1.1%) |
| Mar 2006 | - | $266.10 M(-1.1%) |
| Dec 2005 | $269.14 M(+5.0%) | $269.14 M(+7.9%) |
| Sep 2005 | - | $249.37 M(-1.0%) |
| Jun 2005 | - | $251.94 M(-1.0%) |
| Mar 2005 | - | $254.58 M(-0.7%) |
| Dec 2004 | $256.43 M(-4.7%) | $256.43 M(-0.6%) |
| Sep 2004 | - | $257.91 M(-1.1%) |
| Jun 2004 | - | $260.67 M(-1.9%) |
| Mar 2004 | - | $265.74 M(-1.2%) |
| Dec 2003 | $268.99 M(+30.9%) | $268.99 M(-7.1%) |
| Sep 2003 | - | $289.56 M(+38.8%) |
| Jun 2003 | - | $208.64 M(+1.5%) |
| Mar 2003 | - | $205.46 M(-0.0%) |
| Dec 2002 | $205.47 M(-0.7%) | $205.47 M(+0.2%) |
| Sep 2002 | - | $205.15 M(-0.3%) |
| Jun 2002 | - | $205.81 M(-0.3%) |
| Mar 2002 | - | $206.44 M(-0.3%) |
| Dec 2001 | $207.02 M(+1575.2%) | $207.02 M(+2119.6%) |
| Sep 2001 | - | $9.33 M(-7.4%) |
| Jun 2001 | - | $10.07 M(-7.7%) |
| Mar 2001 | - | $10.92 M(-11.6%) |
| Dec 2000 | $12.36 M(-13.0%) | $12.36 M(-2.0%) |
| Sep 2000 | - | $12.61 M(-3.9%) |
| Jun 2000 | - | $13.12 M(-6.2%) |
| Mar 2000 | - | $13.99 M(-1.5%) |
| Dec 1999 | $14.20 M(-12.9%) | $14.20 M(-5.3%) |
| Sep 1999 | - | $15.00 M(-4.5%) |
| Jun 1999 | - | $15.70 M(-1.9%) |
| Mar 1999 | - | $16.00 M(-1.8%) |
| Dec 1998 | $16.30 M(-13.3%) | $16.30 M(+2.5%) |
| Sep 1998 | - | $15.90 M(-15.4%) |
| Jun 1998 | - | $18.80 M(+1.6%) |
| Mar 1998 | - | $18.50 M(-1.6%) |
| Dec 1997 | $18.80 M(+0.5%) | $18.80 M(+0.5%) |
| Sep 1997 | - | $18.70 M(-3.1%) |
| Jun 1997 | - | $19.30 M(+4.9%) |
| Mar 1997 | - | $18.40 M(-1.6%) |
| Dec 1996 | $18.70 M(+43.8%) | $18.70 M(+6.9%) |
| Sep 1996 | - | $17.50 M(+3.6%) |
| Jun 1996 | - | $16.90 M(+24.3%) |
| Mar 1996 | - | $13.60 M(+4.6%) |
| Dec 1995 | $13.00 M(+41.3%) | $13.00 M(+83.1%) |
| Sep 1995 | - | $7.10 M(-9.0%) |
| Jun 1995 | - | $7.80 M(-9.3%) |
| Mar 1995 | - | $8.60 M(-6.5%) |
| Dec 1994 | $9.20 M(+50.8%) | $9.20 M(+13.6%) |
| Sep 1994 | - | $8.10 M(+9.5%) |
| Jun 1994 | - | $7.40 M(-10.8%) |
| Mar 1994 | - | $8.30 M(+36.1%) |
| Dec 1993 | $6.10 M(0.0%) | $6.10 M(-4.7%) |
| Sep 1993 | - | $6.40 M(-3.0%) |
| Jun 1993 | - | $6.60 M(0.0%) |
| Mar 1993 | - | $6.60 M(+8.2%) |
| Dec 1992 | $6.10 M(+35.6%) | $6.10 M(+8.9%) |
| Sep 1992 | - | $5.60 M(+7.7%) |
| Jun 1992 | - | $5.20 M(0.0%) |
| Mar 1992 | - | $5.20 M(+15.6%) |
| Dec 1991 | $4.50 M(-60.5%) | $4.50 M(+28.6%) |
| Sep 1991 | - | $3.50 M(-10.3%) |
| Jun 1991 | - | $3.90 M(-65.8%) |
| Dec 1990 | $11.40 M | $11.40 M |
FAQ
- What is Regeneron Pharmaceuticals annual total long term liabilities?
- What is the all time high annual total long term liabilities for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals annual total long term liabilities year-on-year change?
- What is Regeneron Pharmaceuticals quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly long term liabilities year-on-year change?
What is Regeneron Pharmaceuticals annual total long term liabilities?
The current annual total long term liabilities of REGN is $4.46 B
What is the all time high annual total long term liabilities for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual total long term liabilities is $4.46 B
What is Regeneron Pharmaceuticals annual total long term liabilities year-on-year change?
Over the past year, REGN annual total long term liabilities has changed by +$777.80 M (+21.11%)
What is Regeneron Pharmaceuticals quarterly total long term liabilities?
The current quarterly long term liabilities of REGN is $4.46 B
What is the all time high quarterly long term liabilities for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly total long term liabilities is $4.46 B
What is Regeneron Pharmaceuticals quarterly long term liabilities year-on-year change?
Over the past year, REGN quarterly total long term liabilities has changed by +$777.80 M (+21.11%)